UNDER EYE

STUDY TEMPLATE

BrighTex Bio-Photonics, LLC
359 Piercy Road, San Jose,
CA 95138 USA
Tel : +1.408.960.3816
Fax : +1.408.960.2916
Website : www.btbp.org
Email : support@btbp.org

ABSTRACT

The main objective is to compare the anti-aging benefits of the '**skin care device used with the specially formulated skin care treatment cleansers (Group A)**' which simultaneously treats and cleanses the skin versus use of the '**skin care treatment cleansers alone (Group B)**'under the eye area.

Participant's captures are taken using Clarity Research 3D System digital photography at Baseline, One Hour Post-Application (±15 Minutes), Week One, Week Two, Week Four, Week Eight and Week Twelve. Measurements will be recorded before and after using the device with specially formulated skin care treatment cleansers and without using the skin care device.

It was concluded that there was a significant improvement at Week 12 compared to baselinein Fine Wrinkles Average Severity that ranges from 25.0% to 58.3%, Wrinkle Object Count which ranges from 41.7% to 66.7% and Average Severity which ranges from 8.3% to 58.3% in Wrinkles 2D,Average Depth which ranges from 33.3% to 83.3%and Total Volume feature which ranges from 41.7% to 66.7%from Wrinkles 3D in Group A.

For Group B, it was concluded that there is statistically significant improvement in Fine Wrinkles Average Severity which ranges from 0.0% to 58.3%, Wrinkle Object Count which ranges from 33.3% to 58.3% and Average Severity which range from 0.0% to 58.3% in Wrinkles 2D, Average Depth which ranges from 8.3% to 66.7% and Total Volume feature which ranges from 25.0% to 66.7% in Wrinkles 3D. Skin Colorfeature showed improvement at Week 12 compared to baseline in Group A& B which ranges from 16.7% to 91.7%.

Section 1:OBJECTIVE

The objective of this study is to compare the anti-aging benefits under the eye area, in the crow's feet region, and under the eyebrow line using the '**skin care device used with the specially formulated skin care treatment cleansers (Group A)**' which simultaneously treats and cleanses the skin versus use of the '**skin care treatment cleansers alone (Group B)**'.

Section 2: STUDYDESIGN

Approximately 12 female Participantsaged between 35-65 with sagging skin and/or visible fine lines and wrinkles on the crow's feet and under eye areas will be enrolled in this study assessing the safety and efficacy of a skin care product alone compared to the skin care product used with a device over a twelve week use period. The study will include Clarity Research 3D System photography. A study schedule appears below.

Procedure	**Baseline**	**One Hour Post-Application (±15 Minutes)**	**Week One**	**Week Two**	**Week Four**	**Week Eight**	**Week Twelve**
Inclusion and Exclusion Criteria Verified	✓						
Informed Consent Obtained	✓						
Test Materials and Daily Diaries Distributed	✓						
Clarity Research 3D System Photography	✓+	✓	✓	✓	✓	✓	✓
Test Materials and Daily Diaries Collected							✓

BrighTex Bio-Photonics, LLC
Your Artificial Intelligence Company

✓Indicates the Participants visit to the Research& Imaging Study Centre laboratory

+ indicates, evaluations will be performed prior to test material application.

Section 3: STUDY POPULATION

Approximately 12 female Participants will be enrolled in this study. Participants will be admitted to the study at the discretion of the Principal Investigator or his/her designate based on medical history, findings of the pre-study interview, and examination.

3.1 INCLUSION CRITERIA

A Participant may be eligible for study participation if all of the following criteria are met:

1. Participant is female between 35 and 65 years of age of any skin type;
2. Participant has a Fitzpatrick Skin Type of I to IV;
3. Participant has sagging skin and/or visible fine lines and wrinkles around the under eye/crow's feet area;
4. Participant agrees to avoid excessive sun exposure for the duration of the study;
5. Participant agrees not to introduce any new cosmetic or skincare products, except for the test material provided for the duration of the study;
6. Participant agrees to only use their regular face wash and moisturizer, but not their regular eye cream, for the duration of the study;
7. Participant is free from any dermatological or systemic disorders which, in the opinion of the Principal Investigator, would interfere with the test results or increase the risk of an adverse reaction;
8. Participant is dependable and able to follow directions as outlined in the protocol;
9. Participant is willing to participate in all study evaluations;
10. Participant is in generally good health and has a current Panelist Profile Form on file at Clarity Research 3D Laboratory;
11. Participant agrees to sign a Photography Release Form, providing consent for the capture of digital images for use in relation to this clinical study;

12. Participant has completed a HIPAA Authorization Form in conformance with 45 CFR Parts 160 and 164;

13. Participant understands and is willing to sign an Informed Consent Form in conformance with 21 CFR Part 50: "Protection of Human Participants."

3.2 EXCLUSION CRITERIA

A Participant is not eligible for study participation if any of the following criteria are met:

1. Participant is known to be pregnant, nursing, planning to become pregnant, or excessive birth control;
2. Participant is being treated for cancer or has a history of facial skin cancer on the test areas;
3. Participant has sunburn, moderate to pronounced suntan, uneven skin tones, tattoos, scars, or other disfiguration, dilated vessels or other conditions on the test area that might influence the test results;
4. Participant has any disease or condition of the skin that the Principal Investigator deems inappropriate for participation, including rosacea, eczema, and atopic dermatitis;
5. Participant is currently taking certain medications, which in the opinion of the Principal Investigator may interfere with the study. This would include but not be limited to routine high dosage use of anti-inflammatory drugs (aspirin, ibuprofen, corticosteroids), immunosuppressive drugs, or antihistamine medications (steroid nose drops and/or eye drops are permitted), and insulin, anti-hypertensive drugs, antibiotics or other topical drugs at the test sites;
6. Participant has uncontrolled metabolic diseases such as diabetes (Type I and II), hypertension, hyperthyroidism or hypothyroidism, severe chronic asthma, immunological disorders such as HIV positive, AIDS and systemic lupus erythematosus or mastectomy for cancer involving removal of lymph nodes;
7. Participant is participating in other facial clinical studies;
8. Participant has routinely used an alpha-hydroxy-acid (AHA) or a beta-hydroxy-acid (BHA) containing product within two weeks or Retin-A, Retin-A Micro, Renova, Differin, Avita,

Tazorac, or Soriatane within one month of the study start or have taken Accutane within one year of the study start. Individuals who have used Retinol in the last six months;

9. Participant has inflammatory acne lesions (i.e., papules, pustules, cysts, nodules) at the test site;

10. Participant has had chemical peels or dermabrasion within the last six months;

11. Participant has known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs;

12. Participant is currently using topically applied prescription medications where the medication is applied on or near the test site;

13. Participant has participated in a similar study within the last seven days. That is, at least one week shall have elapsed since a Participant participated in a facial sting test.

3.3 PARTICIPANT TERMINATION AND WITHDRAWAL

A Participant may be discontinued from study participation at any time if the Principal Investigator or designated medical staffs feels that it is not in the Participant's best interest to continue.

All Participants are free to withdraw from participation at any time, for any reason, specified or unspecified, and without prejudice. Reasonable attempts will be made by the Principal Investigator to provide a reason for Participant withdrawals. The reason for the Participant's withdrawal from the study will be specified in the Participant's source documents and included in the final report.

Section 4: RANDOMIZATION

Side of the face that Participants will use the skin care device with the specially formulated skin care product(Group A) will be assigned in accordance with a computer-generated randomization schedule. Participant will only use the skin care treatment product (without the device) (Group B) on the opposite side of the face.

Section 5: STUDY EVALUATIONS

5.1 CLARITY RESEARCH 3D SYSTEM

The Clarity Research 3D System features the latest technology in 2D and 3D skin modelling, boasting three cameras, each with 25 megapixels and SLR image capture in 16-bit. The Automated image recognition includes artificial intelligence for facial and skin area recognition, high precision facial detection, automation for facial zoning and zoning by area of interest, and data tracking by region of interest. The Clarity Research 3D System captures six types of skin images, including diffuse white light, melanin, haemoglobin, texture, 3D macro structure, and 3D micro structure. The system also allows for simultaneous front, left and right profile capture with no repositioning requirements.

The Clarity Research 3D system is capable of detecting over 50 facial regions for analysis of fine lines, texture, skin tone evenness and discoloration, and contouring. Clarity Research 3D system photography will be captured at Baseline, one hour post-application, Week One, Week Two, Week Four, Week Eight, and Week Twelve. Images will be captured with the eyes open.

5.2 SKIN FEATURE TO BE STUDIED

5.2.1 Skin Color

Human Skin type varies by region and ethnicity. The variance in skin color is primarily due to a pigment known as melanin present underneath the skin layers. Skin Color generally ranges from a very dark brown to a near yellowish pink. Darker skin colors are due to the presence

Measured Parameters: L Star

L Star: As L* increases the brightness in Skin tone increases

The lightness value, L*, represents the darkest black at L*= 0, and the brightest white at L* = 100.

Sample Result Images:

T0



T1



T2



T3



T4



T5



T6



Group A: L Star

Participant 12 Results



Group A - Overall L Star



BrighTex Bio-Photonics, LLC
Your Artificial Intelligence Company

Test Results and Statistical Summary

Clarity™ Mini3D System-Skin Color L Star				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Skin Color L Star	Skin Care Device + Formulated Skin Care Treatment Cleansers (Group A)	One HourPost-Application	6	50.0%
		Week 1	6	50.0%
		Week 2	2	16.7%
		Week 4	10	83.3%
		Week 8	11	91.7%
		Week 12	9	75.0%

Group B: L Star



Group B - Overall L Star



Test Results and Statistical Summary:

Clarity™ Mini3D System-Skin Color L Star				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Skin Color L Star	Formulated Skin Care Treatment Cleansers ONLY (Group B)	One HourPost-Application	6	50.0%
		Week 1	5	41.7%
		Week 2	2	16.7%
		Week 4	10	83.3%
		Week 8	11	91.7%
		Week 12	9	75.0%

5.2.2 Wrinkles 3D

Structural changes in specific parts of the dermis and the subcutaneous tissue producing a fold, ridge or crease on the skin is considered as a wrinkle.

Measured Parameters: Total Volume, Average Depth

i. **Total Volume:** Total wrinkle volume of the recognized wrinkles

T0



T1



T1



T2

T4



T5



T6

Group A: Total Volume

Participant 06 Results



Group A – Overall Total Volume



BrighTex Bio-Photonics, LLC
Your Artificial Intelligence Company

Test Results and Statistical Summary

Clarity™ Mini3D System-Wrinkles 3D Total Volume				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Wrinkles 3D – Total Volume	Skin Care Device + Formulated Skin Care Treatment Cleansers (Group A)	One HourPost-Application	5	41.7%
		Week 1	7	58.3%
		Week 2	6	50.0%
		Week 4	5	41.7%
		Week 8	6	50.0%
		Week 12	8	66.7%

Group B: Total Volume

Participant 06 Results



Group B - Overall Total Volume:



Test Results and Statistical Summary:

Clarity™ Mini3D System-Wrinkles 3D Total Volume				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Wrinkles 3D – Total Volume	Formulated Skin Care Treatment Cleansers ONLY (Group B)	One HourPost-Application	7	58.3%
		Week 1	5	41.7%
		Week 2	8	66.7%
		Week 4	3	25.0%
		Week 8	4	33.3%
		Week 12	7	58.3%

ii. Average Depth: Average Depth of recognized wrinkles

Group A: Average Depth

Participant 06 Results



Group A – Overall Average Depth



Test Results and Statistical Summary:

Clarity™ Mini3D System-Wrinkles 3D Average Depth				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Wrinkles 3D – Average Depth	Skin Care Device + Formulated Skin Care Treatment Cleansers (Group A)	One HourPost-Application	4	33.3%
		Week 1	8	66.7%
		Week 2	7	58.3%
		Week 4	6	50.0%
		Week 8	7	58.3%
		Week 12	10	83.3%

Group B: Average Depth

Participant 06 Results



Group B – Overall Average Depth



Test Results and Statistical Summary

Clarity™ Mini3D System-Wrinkles 3D Average Depth				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Wrinkles 3D – Average Depth	Skin Care Device + Formulated Skin Care Treatment Cleansers (Group B)	One HourPost-Application	1	8.3%
		Week 1	7	58.3%
		Week 2	3	25.0%
		Week 4	8	66.7%
		Week 8	8	66.7%
		Week 12	6	50.0%

5.2.3 Wrinkles 2D

Structural changes in specific parts of the dermis and the subcutaneous tissue producing a fold, ridge or crease on the skin is considered as a wrinkle.

Measured Parameters: Average Severity, Wrinkle Object Count and Fine Wrinkles Average Severity

i. **Average Severity:** It is the average of intensity difference of each wrinkle from its start point to end point of the wrinkle.

Sample Result Images:

T0



T1



T2



T3



T4



T5



T6



Group A: Average Severity

Participant 13 Results



Group A – Overall Average Severity:



BrighTex Bio-Photonics, LLC
Your Artificial Intelligence Company

Test Results and Statistical Summary

Clarity™ Mini3D System-Average Severity				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Wrinkles 2D – Average Severity	Skin Care Device + Formulated Skin Care Treatment Cleansers (Group A)	One HourPost-Application	1	8.3%
		Week 1	3	25.0%
		Week 2	4	33.3%
		Week 4	2	16.7%
		Week 8	3	25.0%
		Week 12	7	58.3%

Group B: Average Severity

Participant 13 Results



Group B – Overall Average Severity:



Test Results and Statistical Summary

Clarity™ Mini3D System-Wrinkles 2D Average Severity				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Wrinkles 2D – Average Severity	Skin Care Device + Formulated Skin Care Treatment Cleansers (Group B)	One HourPost-Application	0	0.0%
		Week 1	0	0.0%
		Week 2	3	25.0%
		Week 4	2	16.7%
		Week 8	2	16.7%
		Week 12	7	58.3%

ii. Wrinkle Object Count: Total Count of the wrinkles in each category i.e. Emerging, Fine, & Deep Wrinkles.

Group A: Wrinkle Object Count

Participant 06 Results



Group A – Overall Wrinkle Object Count:



Test Results and Statistical Summary

Clarity™ Mini3D System-Wrinkles 2D Wrinkles Object Count				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Wrinkles 2D – Wrinkles Object Count	Skin Care Device + Formulated Skin Care Treatment Cleansers (Group A)	One HourPost-Application	5	41.7%
		Week 1	8	66.7%
		Week 2	6	50.0%
		Week 4	5	41.7%
		Week 8	6	50.0%
		Week 12	7	58.3%

Group B: Wrinkle Object Count

Participant 06 Results



BrighTex Bio-Photonics, LLC
Your Artificial Intelligence Company

Group B – Overall Wrinkle Object Count:



Test Results and Statistical Summary

Clarity™ Mini3D System- Wrinkles 2D Wrinkles Object Count				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Wrinkles 2D – Wrinkles Object Count	Formulated Skin Care Treatment Cleansers ONLY (Group B)	One HourPost-Application	5	41.7%
		Week 1	5	41.7%
		Week 2	4	33.3%
		Week 4	7	58.3%
		Week 8	5	41.7%
		Week 12	4	33.3%

iii. Fine Wrinkles Average Severity: Severity represents the average visibility score of Fine Wrinkle Lines with respective to skin color.

Group A: Fine Wrinkles Average Severity

Participant 13 Results



Group A: Overall Fine Wrinkles Average Severity



Test Results and Statistical Summary

Clarity™ Mini3D System-Wrinkles 2D Fine Wrinkles Average Severity				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Wrinkles 2D Fine Wrinkles Average Severity	Skin Care Device + Formulated Skin Care Treatment Cleansers (Group A)	One HourPost-Application	3	25.0%
		Week 1	3	25.0%
		Week 2	4	33.3%
		Week 4	3	25.0%
		Week 8	3	25.0%
		Week 12	7	58.3%

Group B: Fine Wrinkles Average Severity

Participant 13 Results



Group B: Overall Fine Wrinkles Average Severity



Test Results and Statistical Summary

Clarity™ Mini3D System- Wrinkles 2D Fine Wrinkles Average Severity				
Parameter	Treatment	Visit	Number of Participants showed improvement	% of Participants showed improvement
Wrinkles 2D Fine Wrinkles Average Severity	Formulated Skin Care Treatment Cleansers ONLY (Group B)	One HourPost-Application	0	0.0%
		Week 1	1	8.3%
		Week 2	4	33.3%
		Week 4	5	41.7%
		Week 8	1	8.3%
		Week 12	7	58.3%

BrighTex Bio-Photonics, LLC
Your Artificial Intelligence Company

Section 6: TEST METHOD

6.1 PARTICIPANTIDENTIFICATION

All Participants will be initially identified by a permanent Research centre panellist database identification number. Once the Participant meets qualification criteria, a study Participantnumber will be assigned. This permanent Participant number will be assigned in sequence as Participants are enrolled in the study.

6.2 BASELINE VISIT

Participants will arrive at the Research laboratory testing facility for the baseline visit with clean, bare faces, wearing no facial makeup and having refrained from applying any facial products. Inclusion and Exclusion Criteria will be verified and informed consent and photography release forms will be read and signed by each Participant. Participants who meet all the study requirements will be enrolled.

Participants will acclimate to ambient laboratory conditions for approximately 15 minutes. Clarity™ Research 3D System images will be captured (eyes open) of each Participant, as indicated in Section 5.1. A trained Research Laboratory technician will instruct the Participant on how to properly use the device regimen. Participants will be instructed to use the device on the assigned side of the eye area only. The topical product will be applied to both under eye areas. The test material will be used for the first time in the testing facility under the supervision of a trained Research Laboratory technician. One hour post-application Clarity 3D images will be captured.

Participants will be provided with the test material, Daily Diaries, and verbal and written instructions outlining study requirements and restrictions. Dates and appointment times for subsequent study visits will be arranged and documented. Participants will be instructed to use the test material according to the usage instructions for their group, as outlined in product

usage instructionsof this clinical study protocol. Participants will be instructed to track their daily product usage in the Daily Diaries throughout the duration of the study.

6.3 WEEK ONE VISIT

Participants will return to the testing facility following one week of twice daily test material use with clean, bare faces, wearing no facial makeup and having refrained from applying any facial products, with the exception of the test products, which should be applied at least two hours prior to the study visit. Participants will acclimate to ambient laboratory conditions for approximately 15 minutes. Clarity™ Research 3D System images will be captured of each Participant, as indicated in Section 5.1.

Daily diaries will be reviewed by the study personnel for compliance.

6.4 WEEK TWO VISIT

Participants will return to the testing facility following two weeks of twice daily test material use with clean, bare faces, wearing no facial makeup and having refrained from applying any facial products, with the exception of the test products, which should be applied at least two hours prior to the study visit. Participants will acclimate to ambient laboratory conditions for approximately 15 minutes. Clarity™ Research 3D System images will be captured of each Participant, as indicated in Section 5.1.

Daily diaries will be reviewed by the study personnel for compliance.

6.5 WEEK FOUR VISIT

Participants will return to the testing facility following four weeks of twice daily test material use with clean, bare faces, wearing no facial makeup and having refrained from applying any facial products, with the exception of the test products, which should be applied at least two hours prior to the study visit. Participants will acclimate to ambient laboratory conditions for approximately 15 minutes. Clarity™ Research 3D System images will be captured of each Participant, as indicated in Section 5.1.

Daily diaries will be reviewed by the study personnel for compliance.

6.6 WEEK EIGHT VISIT

Participants will return to the testing facility following eight weeks of twice daily test material use with clean, bare faces, wearing no facial makeup and having refrained from applying any facial products, with the exception of the test products, which should be applied at least two hours prior to the study visit. Participants will acclimate to ambient laboratory conditions for approximately 15 minutes. Clarity™ Research 3D System images will be captured of each Participant, as indicated in Section 5.1.

Daily diaries will be reviewed by the study personnel for compliance.

6.7 WEEK TWELVE VISIT

Participants will return to the testing facility following twelve weeks of twice daily test material use with clean, bare faces, wearing no facial makeup and having refrained from applying any facial products, with the exception of the test products, which should be applied at least two hours prior to the study visit. Participants will acclimate to ambient laboratory conditions for approximately 15 minutes. Clarity™ Research 3D System images will be captured of each Participant, as indicated in Section 5.1.

Daily diaries will be reviewed by the study personnel for compliance and collected. Test devices and unused test materials will be collected.

Section 7: Product Usage Instructions

7.1 Skin Care Device + Formulated Skin Care Treatment Cleansers

Participant will use the skin care device with formulated skin care treatment cleansers on the under eye area/crow's feet and under eyebrow region for 30 seconds on one randomized side. The treatment will be done twice daily.

7.2 Formulated Skin Care Treatment Cleansers ONLY

Participant will use the skin care treatments cleansers on the under eye area/crow's feet and under eyebrow region one the other side. The treatment will be done twice daily.

7.3 Skin Care Device Usage

7.3.1 Attaching theSkinCare DeviceTreatment Head

• Grip the sides of the Accent with the head at the top and the curve at the bottom.

• Align the hole on the back of the treatment surface with the black rotating axle on the device hand set.

• Gently press the head onto the axle until it clicks

• Ensure the silicone tip is in place. If needed, align the pattern on the back of the silicone tip to the tip of the device head and press into place.

7.3.2 Using Skin Care Device

- Skin care device is for targeted treatment. Use it morning and night for best results.

Step 1

- After cleansing and toning, apply an ample amount of skin care topical to the desired area of your face.

Step 2

• Turn on the device by pressing the On/Off button.

• Each of the four lights around the centre button will flash once and Accent head will immediately begin to oscillate, first slowly, and then up to normal speed.

• Gently glide the silicone tip of the Accent head over the targeted area gently using slow motions. Do not scrub or move across the skin quickly.

• The device will briefly stop every 30 seconds to prompt you to move to another targeted area.

• Treat both eye areas for 30 seconds each, one-minute total between both eyes, then press the On / Off button to turn the device off.

• Gently massage the remaining product into skin. NOTE: Replace silicone tip every three months.

NOTE: Replace silicone tip every three months.

7.3.3 Cleaning and Caring for Your Skin Care Device

After every treatment:

• Remove the skin care device silicone tip by gently pulling it from the device head. Rinse it with water while gently rubbing the silicone time to remove any excess product.

• Remove the Accent head from the handset (see below). Rinse it with warm water or wipe it down with a damp cloth to remove residual product.





• Dry the Accent head thoroughly, ensuring the treatment head is laid flat.

• Only reattach the Accent head and silicone tip to the handset after all components are thoroughly dry.

7.3.4 Troubleshooting the Skin Care Device

If you would like to pause your treatment, the device can be paused at any time be pressing the On/Off button once. If the device is left paused, then it will turn off after two minutes. If the skin care device head becomes dislodged during use, simply pause the device by pressing the On/Off button and reattach it. Press the On/Off button again to continue treatment. Use slower, more gentle movements to help mitigate these occurrences.

Caution: Do not use the skin care device without the silicone tip in place.

Section 8: CONCLUSION

Various feature parameter measurements are recorded and it was concluded that Wrinkles 2D, Wrinkles 3D and Skin Color showed significant improvement at Week 12 compared to Baseline in Group A and Group B.

The following parameters showed improvements in Group A for Wrinkles 2D: Fine Wrinkles Average Severity which ranges from 25.0% to 58.3%, Wrinkle Object Countwhich ranges from 41.7% to 66.7% and Average Severity which ranges from 8.3% to 58.3%.

The following parameters showed improvements in Group B for Wrinkles 2D: Fine Wrinkles Average Severity which ranges from 0.0% to 58.3%, Wrinkle Object Count which ranges from 33.3% to 58.3% and Average Severity which range from 0.0% to 58.3%.

The following parameters showed improvements in Group A for Wrinkles 3D: Average Depth which ranges from 33.3% to 83.3% and Total Volume features which range from 41.7% to 66.7%.

The following parameters showed improvements in Group B for Wrinkles 3D: Average Depth which ranges from 8.3% to 66.7% and Total Volume feature which ranges from 25.0% to 66.7%.

The following parameters showed improvements in Group A and Group B for Skin Color: L Star feature which range from 16.7% to 91.7% in Group A and Group B.